Southwest oncology group strategies in prostatic carcinoma

E. David Crawford; Maha Hussain; Edward P. Deantoni; Ian M. Thompson; Mario A. Eisenberger; Brent Blumenstein; Charles A. Coltman

doi:10.1002/ssu.2980110109

Southwest oncology group strategies in prostatic carcinoma

E. David Crawford, Maha Hussain, Edward P. Deantoni, Ian M. Thompson, Mario A. Eisenberger, Brent Blumenstein, Charles A. Coltman

School of Medicine

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

The Southwest Oncology Group Genitourinary Committee evolved in 1978 from a combined gynecologie‐urologie cancer committee. A significant catalyst in this development was the growing interest in prosta‐tic carcinoma, with an initial focus on hormone refractory disease. Clinical studies have expanded into combined androgen blockade, untreated metastatic disease and localized prostate cancer. Since 1978, more than forty trials in prostatic carcinoma have been conducted. Currently, seven are in progress or under development. Conclusions and future directions are reviewed. © 1995 Wiley‐Liss, Inc.

Original language	English (US)
Pages (from-to)	60-64
Number of pages	5
Journal	Seminars in surgical oncology
Volume	11
Issue number	1
DOIs	https://doi.org/10.1002/ssu.2980110109
State	Published - 1995

Keywords

advanced disease
clinical trials
prostate cancer

ASJC Scopus subject areas

Surgery
Oncology

Access to Document

10.1002/ssu.2980110109

Cite this

@article{e2f6a94afa8b44778a1376784b39dd19,

title = "Southwest oncology group strategies in prostatic carcinoma",

abstract = "The Southwest Oncology Group Genitourinary Committee evolved in 1978 from a combined gynecologie‐urologie cancer committee. A significant catalyst in this development was the growing interest in prosta‐tic carcinoma, with an initial focus on hormone refractory disease. Clinical studies have expanded into combined androgen blockade, untreated metastatic disease and localized prostate cancer. Since 1978, more than forty trials in prostatic carcinoma have been conducted. Currently, seven are in progress or under development. Conclusions and future directions are reviewed. {\textcopyright} 1995 Wiley‐Liss, Inc.",

keywords = "advanced disease, clinical trials, prostate cancer",

author = "Crawford, {E. David} and Maha Hussain and Deantoni, {Edward P.} and Thompson, {Ian M.} and Eisenberger, {Mario A.} and Brent Blumenstein and Coltman, {Charles A.}",

year = "1995",

doi = "10.1002/ssu.2980110109",

language = "English (US)",

volume = "11",

pages = "60--64",

journal = "Journal of Surgical Oncology",

issn = "0022-4790",

publisher = "Wiley-Liss Inc.",

number = "1",

}

TY - JOUR

T1 - Southwest oncology group strategies in prostatic carcinoma

AU - Crawford, E. David

AU - Hussain, Maha

AU - Deantoni, Edward P.

AU - Thompson, Ian M.

AU - Eisenberger, Mario A.

AU - Blumenstein, Brent

AU - Coltman, Charles A.

PY - 1995

Y1 - 1995

N2 - The Southwest Oncology Group Genitourinary Committee evolved in 1978 from a combined gynecologie‐urologie cancer committee. A significant catalyst in this development was the growing interest in prosta‐tic carcinoma, with an initial focus on hormone refractory disease. Clinical studies have expanded into combined androgen blockade, untreated metastatic disease and localized prostate cancer. Since 1978, more than forty trials in prostatic carcinoma have been conducted. Currently, seven are in progress or under development. Conclusions and future directions are reviewed. © 1995 Wiley‐Liss, Inc.

AB - The Southwest Oncology Group Genitourinary Committee evolved in 1978 from a combined gynecologie‐urologie cancer committee. A significant catalyst in this development was the growing interest in prosta‐tic carcinoma, with an initial focus on hormone refractory disease. Clinical studies have expanded into combined androgen blockade, untreated metastatic disease and localized prostate cancer. Since 1978, more than forty trials in prostatic carcinoma have been conducted. Currently, seven are in progress or under development. Conclusions and future directions are reviewed. © 1995 Wiley‐Liss, Inc.

KW - advanced disease

KW - clinical trials

KW - prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=0028896348&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028896348&partnerID=8YFLogxK

U2 - 10.1002/ssu.2980110109

DO - 10.1002/ssu.2980110109

M3 - Article

C2 - 7754277

AN - SCOPUS:0028896348

SN - 0022-4790

VL - 11

SP - 60

EP - 64

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

IS - 1

ER -

Southwest oncology group strategies in prostatic carcinoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this